163 related articles for article (PubMed ID: 30867272)
1. A survey of risk tolerance to multiple sclerosis therapies.
Fox RJ; Cosenza C; Cripps L; Ford P; Mercer M; Natarajan S; Salter A; Tyry T; Cofield SS
Neurology; 2019 Apr; 92(14):e1634-e1642. PubMed ID: 30867272
[TBL] [Abstract][Full Text] [Related]
2. Risk tolerance to MS therapies: Survey results from the NARCOMS registry.
Fox RJ; Salter A; Alster JM; Dawson NV; Kattan MW; Miller D; Ramesh S; Tyry T; Wells BW; Cutter G
Mult Scler Relat Disord; 2015 May; 4(3):241-9. PubMed ID: 26008941
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
Heesen C; Kleiter I; Meuth SG; Krämer J; Kasper J; Köpke S; Gaissmaier W
J Neurol Sci; 2017 May; 376():181-190. PubMed ID: 28431609
[TBL] [Abstract][Full Text] [Related]
4. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
5. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
Schweitzer F; Laurent S; Fink GR; Barnett MH; Reddel S; Hartung HP; Warnke C
Curr Opin Neurol; 2019 Jun; 32(3):305-312. PubMed ID: 30985373
[TBL] [Abstract][Full Text] [Related]
6. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
8. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
[TBL] [Abstract][Full Text] [Related]
9. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
10. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
Mills EA; Mao-Draayer Y
Mult Scler; 2018 Jul; 24(8):1014-1022. PubMed ID: 29774781
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis, natalizumab, and PML: helping patients decide.
Rudick RA
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
13. Infection risk in patients on multiple sclerosis therapeutics.
Williamson EM; Berger JR
CNS Drugs; 2015 Mar; 29(3):229-44. PubMed ID: 25761739
[TBL] [Abstract][Full Text] [Related]
14. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
15. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
16. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
Enzinger C
Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038
[No Abstract] [Full Text] [Related]
17. Multiple sclerosis risk perception and acceptance for Brazilian patients.
Bichuetti DB; Franco CA; Elias I; Mendonça ACR; Carvalho LFD; Diniz DS; Tur C; Tintoré M; Oliveira EML
Arq Neuropsiquiatr; 2018 Jan; 76(1):6-12. PubMed ID: 29364388
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
19. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
20. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
